STAT Plus: Watch: The state of biotech at time of innovation — and high prices
CAMBRIDGE, Mass. — We live in an age of miracles, but they come at a…
Author: STAT
Having gobbled up Celgene, the Bristol-Myers CEO ducks questions about his key rival
CAMBRIDGE, Mass. — In his first appearance since Bristol-Myers Squibb completed its takeover last week…
.jpg)
Biogen’s top scientist nearly dares FDA not to approve Alzheimer’s drug
Biogen’s top scientist offered unflinching support Thursday for the efficacy of the company’s controversial Alzheimer’s…
Across several continents, infecting mosquitoes with bacteria results in dramatic drops in dengue illness, trials show
The number of people infected by dengue and at least one related virus has plunged…
STAT Plus: A bold prediction: Machine learning will yield new drug candidates within three years
CAMBRIDGE, Mass. — An explosion of biological data will lead to the first drug candidates…
STAT Plus: ‘The industry has earned it’: Three CEOs own up to biopharma’s bad reputation
CAMBRIDGE, Mass. — Biopharma’s reputation is, objectively speaking, the worst. And on Thursday, several biotech…
STAT Plus: Gene therapy pioneer says the field is behind — and that delivery technology is ‘embarrassing’
CAMBRIDGE, Mass. — Gene therapy pioneer Dr. James Wilson is disappointed by the progress in…
STAT Plus: Pharmalittle: Trump and senators push for drug prices in TV ads; Sanofi looks to spin off consumer business
Top of the morning to you, and a fine one it is. We may have…
Gilead CEO Daniel O’Day says company is in an ‘acquisitive mode’
CAMBRIDGE, Mass. — Daniel O’Day, in his eight months on the job as CEO of…
STAT Plus: Patient charity settles allegations it helped MS drug makers pay kickbacks
A patient assistance charity has agreed to pay $4 million to settle allegations that it…
FDA approves Alnylam’s Givlaari, second-ever drug based on RNAi
The FDA has approved the second-ever drug based on a Nobel prize-winning technique known as…
Stephen Hahn, Trump’s FDA nominee, pledges ‘bold action’ on vaping but sidesteps questions on flavor ban
WASHINGTON — President Trump’s nominee to lead the Food and Drug Administration, faced with a…
STAT Plus: Pharmalittle: Purdue affiliate in China pushes misleading opioid claims; more generics are approved but not yet available
Hello, everyone, and nice to see you again after a brief sojourn in a foreign…
OxyContin maker thrives in China with abandoned U.S. tactics
SHANGHAI — OxyContin is a dying business in the United States. Purdue Pharma, owned by…
Opinion: Some bipartisan support for biosimilars is good. More would be better
In today’s hyperpartisan and gridlocked political climate, we should seize any opportunity for bipartisan agreement…
Opinion: Letting academic medical centers make CAR-T drugs would save billions
Draw blood from someone with cancer. Engineer their blood cells to seek and destroy cancer….
STAT Plus: Biotech venture capitalists form a lobbying coalition to join the drug pricing debate
A shorter version of this story first appeared in D.C. Diagnosis, STAT’s weekly newsletter about…
Trump’s stalling on flavored vape ban draws blowback — and fears of lasting damage to American health
The Trump administration’s apparent decision to back off a plan to ban flavored e-cigarettes has…
.jpg)
STAT Plus: Pharmalittle: How Purdue planted its ‘anti-story’; how much does that ‘free’ flu shot cost?
Good morning. Elizabeth Cooney here again in Boston while Ed Silverman completes another engagement abroad….
First CRISPR treatment for blood diseases shows early benefits in two patients
The first two patients to receive a CRISPR-based treatment for the inherited blood disorders sickle…
STAT Plus: Novo Nordisk’s parent company to launch research incubator in Boston
Novo Holdings, the investment firm behind pharmaceutical giant Novo Nordisk, is committing $25 million over…
How Purdue planted its ‘anti-story’ and delayed the reckoning for its role in the opioid epidemic
This story is a collaboration between STAT and ProPublica. In 2004, Purdue Pharma was facing…
Opinion: In the hospital supply chain, too many choices can be costly
Not long ago, I did a small experiment at a hospital in Texas: I put…
Opinion: Booker-Sanders-Harris drug affordability bureau could be brilliant
In response to growing bipartisan outrage over prescription drug prices, Sens. Cory Booker (D-N.J.), Bernie…
STAT Plus: Amarin releases interim EVAPORATE data — and mineral oil makes another appearance
PHILADELPHIA — Dr. Matthew Budoff probably didn’t want to bury the lede. On Monday, the UCLA…
STAT Plus: Alkermes buys Rodin Therapeutics for up to $950 million, giving it possible avenue for growth
Alkermes announced Monday it would acquire Rodin Therapeutics, a Boston-based biotech developing drugs intended to…
STAT Plus: Pharmalittle: VCs warn Congress on drug-pricing bill; drugs look better than surgery or stents
Good morning. Elizabeth Cooney here in wintry Boston, sitting in for Ed Silverman while he…
STAT Plus: A new approach to treating schizophrenia delivers positive results in mid-stage trial
Boston-based biotech Karuna Therapeutics (KRTX) said Monday that a novel combination pill achieved the main…
Opinion: President Trump: Don’t fail America’s children on flavored e-cigarettes
Optimism among public health advocates regarding the Trump administration’s pending action on flavored e-cigarettes, which…
Calling for federal action, watchdog says there’s no evidence dietary supplements for infertility help women get pregnant
A health and science watchdog group petitioned federal regulators on Monday to take enforcement action…
Big study casts doubt on need for many heart procedures
PHILADELPHIA — People with severe but stable heart disease from clogged arteries may have less…
STAT Plus: Roche buying Promedior for $390 million to develop drugs for fibrotic disease
The Swiss drug giant Roche has agreed to pay $390 million upfront for a Lexington,…
STAT Plus: As first lab-made yeast genome nears completion, scientists set sights on improved human ones
NEW YORK — For a project born in a cauldron of controversy three years ago,…
Opinion: The U.S. needs extra action to eliminate viral hepatitis, the nation’s deadliest infectious disease
I traveled to Boston last weekend for the annual meeting of the American Association for…
Opinion: Adult vaccination saves lives. Why do so few adults get vaccinated?
Vaccines are among the simplest, most effective, and least expensive ways to prevent serious, and…
In a ‘Wild West’ environment, hospitals differ sharply in what patient data they give Google
In deals struck across the U.S., hospital systems appear to be adopting starkly different protocols…
A drug maker courted controversy when it shut out a family-run rival. Now some patients say the medicine isn’t working
Last February, Barbara Moore switched to a new medicine to combat a rare neuromuscular disease…
Listen: Google’s data grab, problematic genetic testing, & the perils of biotech Twitter
Do you trust Google with your health data? Is “Gattaca” an outdated reference? And what’s…
FDA slams Dollar Tree for purchasing drugs from suppliers with checkered safety records
Amid growing concerns over the pharmaceutical supply chain, regulators sternly warned the Dollar Tree (DLTR),…
Apple launches virtual health studies aiming to enroll hundreds of thousands of customers
SAN FRANCISCO — Apple on Thursday launched three observational studies — focused on mobility, menstruation,…
Opinion: Working with ICER, or around it, on cost-effectiveness estimates
As the national debate over prescription drug pricing reaches a fever pitch, drug manufacturers bringing…
Opinion: The FDA must pull Makena off the market
Should doctors be able to prescribe and use a drug that doesn’t work, and may…
In France, it’s illegal for consumers to order a DNA spit kit. Activists are fighting over lifting the ban
PARIS — From scanning her resume, you’d never guess Nathalie Jovanovic-Floricourt was an expert enabler…
STAT Plus: An FDA advisory panel is reviewing Amarin’s fish oil drug. Follow along for frequent updates
We’re monitoring Thursday’s meeting of the Food and Drug Administration advisory committee that is reviewing…
More trial results are being posted to public database, but data quality is lacking, report finds
A new report examining the first decade of study results being reported on ClinicalTrials.gov finds…
STAT Plus: After backlash, Teva will resume supplies of a critical children’s cancer medicine
In an about-face, Teva Pharmaceutical is resuming supplies of a critical cancer medicine for children…
HHS to probe whether Google’s ‘Project Nightingale’ followed federal privacy law
A federal regulator is investigating whether the federal privacy law known as HIPAA was followed…
Opinion: My daughter is gone but her legacy lives on through her writing and phage therapy
“Who lives, who dies, who tells your story?” That line from the musical “Hamilton” inspires…
Opinion: Abundant research shows gender disparities in medicine, but too few know about it. #NeedHerScience
Medicine has an abundance of highly trained and qualified women. So why are there so…
Opinion: STAT Plus: Microbiome drug development: a rapidly evolving field
Ground-breaking research on the microbiome — the collection of bacteria, fungi, and other microbes that…